Соединенные Штаты - английский - NLM (National Library of Medicine)

teva women's health llc - levonorgestrel (unii: 5w7sia7yzw) (levonorgestrel - unii:5w7sia7yzw), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - levonorgestrel 0.1 mg - loseasonique® is indicated for use by females of reproductive potential to prevent pregnancy. loseasonique is contraindicated in females who are known to have or develop the following conditions: - a high risk of arterial or venous thrombotic diseases. examples include females who are known to: smoke, if over age 35 [see boxed warning and warnings and precautions (5.1)] have current or history of deep vein thrombosis or pulmonary embolism [see warnings and precautions (5.1)] have cerebrovascular disease [see warnings and precautions (5.1)] have coronary artery disease [see warnings and precautions (5.1)] have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation) [see warnings and precautions (5.1 )] have inherited or acquired hypercoagulopathies [see warnings and precautions (5.1 )] have uncontrolled hypertension or hypertension with vascular disease [see warnings and precautions (5.5)]

Соединенные Штаты - английский - NLM (National Library of Medicine)

teva women's health llc - levonorgestrel (unii: 5w7sia7yzw) (levonorgestrel - unii:5w7sia7yzw), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - levonorgestrel 0.15 mg - seasonique® is indicated for use by females of reproductive potential to prevent pregnancy. seasonique is contraindicated in females who are known to have or develop the following conditions: - a high risk of arterial or venous thrombotic diseases. examples include females who are known to: smoke, if over age 35 [see boxed warning and warnings and precautions (5.1)]. have current or history of deep vein thrombosis or pulmonary embolism [see warnings and precautions (5.1)]. have cerebrovascular disease [see warnings and precautions (5.1)] have coronary artery disease [see warnings and precautions (5.1)]. have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation) [see warnings and precautions (5.1)]. have inherited or acquired hypercoagulopathies [see warnings and precautions (5.1)]. have uncontrolled hypertension or hypertension with vascular disease [see warnings and precautions ( 5.3 )].

Сингапур - английский - HSA (Health Sciences Authority)

novo nordisk pharma (singapore) pte ltd - eptacog alfa (activated)/rfviia - injection, powder, for solution - 1mg - eptacog alfa (activated)/rfviia 1mg

Сингапур - английский - HSA (Health Sciences Authority)

novo nordisk pharma (singapore) pte ltd - eptacog alfa (activated)/rfviia - injection, powder, for solution - 2mg - eptacog alfa (activated)/rfviia 2mg

Австралия - английский - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - soya oil, quantity: 6 g/l; olive oil, quantity: 24 g/l - injection, intravenous infusion - excipient ingredients: nitrogen; water for injections; sodium hydroxide; egg lecithin; sodium oleate; glycerol - olimel/periolimel is indicated for parenteral nutrition for adults when oral or enteral nutrition is impossible, insufficient or contraindicated.

Австралия - английский - APVMA (Australian Pesticides and Veterinary Medicines Authority)

ceva animal health pty ltd - neomycin sulfate; lignocaine hydrochloride; hydrocortisone - topical cream, ointment, paste, gel, lotion - neomycin sulfate antibiotic active 5.0 mg/g; lignocaine hydrochloride caine active 5.0 mg/g; hydrocortisone steroid-glucocorticoid active 5.0 mg/g - dermatological preps. - animal - antibiotic - anti-infective | abrasions | abscesses | airsacculitis | antiseptic | avian mycoplasmas | blackhead | body odours | bowed tendons | broad spectrum | burns | coccidiosis | coliform complex | conjunctivitis | cowpox | cracks | crusts | dandruff | dermatological disorders | dermatosis | dry skin | dysentery | eczema | endometritis | enteric diseases | enzootic pneumonia | feed efficiency | fungal infections | girth galls | infections | inflammed pads | itching | keratolytic | lacerations | mastitis | mycoplasmas | odours | open wounds | otitis | pruritis | queensland itch | respiratory disease | saddle rash | salmonellosis | scabs | scaly skin | sheath rot | skin irritations | sores | swine dysentery | teat cracking | teat infections | topical infections | udder sores | weight gain | wire cuts | wounds

Израиль - английский - Ministry of Health

baxter healthcare distribution ltd., israel - arginine; calcium chloride dihydrate; glycine; histidine; isoleucine; l- alanine; leucine; lysine hydrochloride; magnesium chloride hexahydrate; methionine; phenylalanine; proline; serine; sodium (s) - lactate; sodium chloride; threonine; tryptophan; tyrosine; valine - solution for peritoneal dialysis - tyrosine 0.3 g/l; tryptophan 0.27 g/l; phenylalanine 0.57 g/l; threonine 0.646 g/l; serine 0.51 g/l; proline 0595 g/l; glycine 0.51 g/l; l- alanine 0.951 g/l; valine 1.393 g/l; methionine 0.85 g/l; isoleucine 0.85 g/l; leucine 1.02 g/l; histidine 0.714 g/l; arginine 1.071 g/l; sodium chloride 5.38 g/l; lysine hydrochloride 0.955 g/l; calcium chloride dihydrate 0.184 g/l; magnesium chloride hexahydrate 0.051 g/l; sodium (s) - lactate 4.480 g/l - combinations of electrolytes - combinations of electrolytes - nutritional supplement for malnourished renal failure patients (albumin concentration lower then 35 g/liter) being maintained on peritoneal dialysis.

Европейский союз - английский - EMA (European Medicines Agency)

novo nordisk a/s - eptacog alfa (activated) - hemophilia b; thrombasthenia; factor vii deficiency; hemophilia a - antihemorrhagics - novoseven is indicated for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in the following patient groups:in patients with congenital haemophilia with inhibitors to coagulation factors viii or ix > 5 bethesda units (bu);in patients with congenital haemophilia who are expected to have a high anamnestic response to factor-viii or factor-ix administration;in patients with acquired haemophilia;in patients with congenital factor-vii deficiency;in patients with glanzmann's thrombasthenia with antibodies to platelet glycoprotein (gp) iib-iiia and / or human leucocyte antigens (hla), and with past or present refractoriness to platelet transfusions.in patients with glanzmann’s thrombasthenia with past or present refractoriness to platelet transfusions, or where platelets are not readily available. 

Австралия - английский - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - rosuvastatin calcium, quantity: 5.21 mg - tablet, film coated - excipient ingredients: magnesium stearate; microcrystalline cellulose; lactose; light magnesium oxide; crospovidone; hypromellose; triacetin; titanium dioxide; lactose monohydrate; iron oxide yellow - cavstat 5 should be used as an adjunct to diet when the response to diet and exercise is inadequate. ,prevention of cardiovascular events cavstat 5 is indicated for prevention of major cardiovascular events in men ?50 years old and women ?60 years old with no clinically evident cardiovascular disease but with at least two conventional risk factors for cardiovascular disease (hypertension, low hdl-c, smoking, or a family history of premature coronary heart disease). cavstat 5 is indicated to:,? reduce the risk of nonfatal myocardial infarction ? reduce the risk of nonfatal stroke ? reduce the risk of coronary artery revascularisation procedures.,in patients with hypercholesterolaemia cavstat 5 is indicated for the treatment of hypercholesterolaemia (including familial hypercholesterolaemia). ,prior to initiating therapy with cavstat 5, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

Австралия - английский - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - rosuvastatin calcium, quantity: 10.42 mg - tablet, film coated - excipient ingredients: magnesium stearate; light magnesium oxide; lactose; crospovidone; microcrystalline cellulose; titanium dioxide; lactose monohydrate; hypromellose; triacetin; brilliant blue fcf aluminium lake; iron oxide red; quinoline yellow aluminium lake - cavstat 10 should be used as an adjunct to diet when the response to diet and exercise is inadequate. ,prevention of cardiovascular events cavstat 10 is indicated for prevention of major cardiovascular events in men ?50 years old and women ?60 years old with no clinically evident cardiovascular disease but with at least two conventional risk factors for cardiovascular disease (hypertension, low hdl-c, smoking, or a family history of premature coronary heart disease). cavstat 10 is indicated to:,? reduce the risk of nonfatal myocardial infarction ? reduce the risk of nonfatal stroke ? reduce the risk of coronary artery revascularisation procedures.,in patients with hypercholesterolaemia cavstat 10 is indicated for the treatment of hypercholesterolaemia (including familial hypercholesterolaemia). ,prior to initiating therapy with cavstat 10, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.